OSCR
Oscar Health, Inc.
OSCR offers stronger fundamentals, but that advantage does not outweigh its weaker overall profile.
SYK
Stryker Corporation
SYK has the edge over OSCR overall, supported by lower modeled downside and stronger valuation.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
SYK Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Strong | |
| Strong | |
| Healthy |
SYK's profitability, cash flow and balance sheet are currently healthy, and its revenue is stable.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR has the edge over SYK in the historical PE scenario, which offers more potential upside but is not a forecast.
SYK PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 20x | $312 | — |
| Current | 33x | $312 | — |
| Cheap | 37x | $344 | +10% |
| Fair | 43x | $402 | +29% |
| Expensive | 51x | $480 | +54% |
Historical ranges are pointers, not guarantees.
SYK's PE is in its cheap range at 33x. If earnings grow as analysts expect, today's price would be 20x next year's earnings.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
OSCR has the edge over SYK on the outlook, with more favorable profitability expectations.
SYK Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Growth | |
| Growth | |
| Stable | |
| Moderate | |
| Moderate |
Analysts expect earnings and revenue growth for SYK, with profitability holding steady.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has returned to profit: it earned $2.47 per share over the past year, after losing money the year before.
SYK Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $15.99 | +70% |
| Q3 2026 | $9.39 | +23% |
| Q2 2026 | $9.65 | +28% |
| Q1 2026 | $8.64 | +17% |
| Q4 2025 | $8.40 | +8.2% |
| Q3 2025 | $7.61 | -18% |
| Q2 2025 | $7.55 | -16% |
| Q1 2025 | $7.40 | -16% |
| Q4 2024 | $7.76 | -5.9% |
SYK earned $9.39 per share over the past year, up 23% from the year before.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over SYK on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR's operating margin was 3.5% last quarter, up 7.8 points from the same quarter a year ago.
SYK Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $6.5B | +7.6% |
| Q2 2026 | $6.6B | +9.4% |
| Q1 2026 | $6B | +2.6% |
| Q4 2025 | $7.2B | +11% |
| Q3 2025 | $6.1B | +10% |
| Q2 2025 | $6B | +11% |
| Q1 2025 | $5.9B | +12% |
| Q4 2024 | $6.4B | +11% |
SYK's revenue has grown year over year every quarter since late 2020: $6.5B last quarter, up 7.6% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 16% | -2.9 points |
| Q2 2026 | 25% | +6.7 points |
| Q1 2026 | 16% | +1.3 points |
| Q4 2025 | 25% | +16 points |
| Q3 2025 | 19% | -1 points |
| Q2 2025 | 18% | -0.9 points |
| Q1 2025 | 14% | -4.3 points |
| Q4 2024 | 9% | -13 points |
SYK has the edge over OSCR on profitability, with a higher operating margin.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR usually generates cash, though not every quarter: the latest was −$1.2B, but it generated $4.1B over the past year.
SYK Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $1.2B | -9.5% |
| Q2 2026 | $1.1B | +14% |
| Q1 2026 | $415M | +227% |
| Q4 2025 | $1.9B | +13% |
| Q3 2025 | $1.4B | +3.8% |
| Q2 2025 | $928M | +93% |
| Q1 2025 | $127M | +243% |
| Q4 2024 | $1.7B | +20% |
SYK has the edge over OSCR on cash flow, with more consistent year-over-year improvement.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
SYK Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -1.3M shares |
| 1 year | -0.5% | -2M shares |
| 3 years | +0.2% | +700K shares |
| 5 years | +0.5% | +2M shares |
| Available history | +1.3% | +4.8M shares |
SYK has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2021 | — |
| Q1 2021 | — |
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
| Q4 2019 | — |
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has the edge over SYK on leverage, with a lower net debt burden relative to earnings.
SYK Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.7x | Healthy |
| Q2 2026 | 1.6x | Healthy |
| Q1 2026 | 1.8x | Healthy |
| Q4 2025 | 1.8x | Healthy |
| Q3 2025 | 2.6x | Moderate |
| Q2 2025 | 2.9x | Moderate |
| Q1 2025 | 3.1x | Elevated |
| Q4 2024 | 2.1x | Moderate |
SYK's net debt is about 1.6 years of its operating earnings (EBITDA), down from 2.6 years a year ago.
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
SYK Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 50.4 | Neutral |
| Stochastic | 51.7 | Neutral |
SYK's weekly RSI is 50 (neutral) and its Stochastic is 52 (neutral).
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR has the edge over SYK on valuation relative to its sector.
SYK PE vs Healthcare Sector
| Metric | SYK | Sector median | Relative |
|---|---|---|---|
| PE | 33x | 26x | 29% above |
| PE % | 9 | 29 | 20 pts below |
SYK is trading at 33x earnings, a 29% premium to the Healthcare sector's median of 26x.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over SYK on trend strength, trading above more of its moving averages.
SYK Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $294.6 | 6% above |
| 20 week MA | $309.1 | 1.1% above |
| 50 week MA | $327.6 | 4.6% below |
| 100 week MA | $352.1 | 11% below |
| 200 week MA | $333.6 | 6.4% below |
SYK has bounced recently, but its long-term trend is still down: it's above its 8- and 20-week averages, but 6.4% below its 200-week average.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over SYK on returns for 2026, with the stronger performance.
SYK Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $210.6 | $237.1 | +13% |
| 2021 | $237.1 | $268.3 | +13% |
| 2022 | $268.3 | $242.8 | -9.5% |
| 2023 | $242.8 | $299.5 | +23% |
| 2024 | $299.5 | $367.1 | +23% |
| 2025 | $367.1 | $354.2 | -3.5% |
| 2026 YTD | $354.2 | $312.4 | -12% |
SYK has finished higher in four of the last six years. It's down 12% so far in 2026.